News NYU Langone Researchers Report What Happens When Multiple Sclerosis Patients Abandon Treatment NYU Langone Researchers Report What Happens When Multiple Sclerosis Patients Abandon Treatment by Patricia Silva, PhD | April 23, 2015 Share this article: Share article via email Copy article link A team led by researchers at the New York University (NYU) Langone Medical Center recently assessed what happens when clinically stable patients with multiple sclerosis (MS) stop taking their medication and found that almost 40% of them experience to some extent a return in disease activity and related symptoms. The results of this study wereĀ presented onĀ April 22, 2015 duringĀ the American Academy of Neurology Annual Meeting being held in Washington, D.C, Poster Session V ā P5.192 entitled āDoctor, can I stop my medicine? Analysis of disease course after stopping disease-modifying therapy in stable MS patients.ā MS is a chronic, progressive neurodegenerative disorder that results from the attack onĀ the central nervous system by the bodyās own immune system, causing inflammation and damage to the myelin layer that covers and protects neurons. Myelin loss leads to impairment in signal transmission along nerve fibers, affecting motor function (like coordination, balance, speech and vision), causing irreversible neurological disability and partial or complete paralysis. It is estimated that more than 2.3 million people in the world suffer from MS. Disease-modifying medication can help in the management of MS by reducing the symptoms and slowing disease progression. According to the National Multiple Sclerosis Society (NMSS), some patients, however, abandon medication due to related side effects, the fact that they still have exacerbations, the perception that they are not feeling better or due to insurance reasons. āDecisions regarding stopping disease-modifying therapy may have implications for short and long-term prognosis. We know a lot about what happens when therapy is started, but we know very little about what happens when therapy is stopped,ā noted the studyās lead author Dr. Ilya Kister in aĀ NYU Langone press release. The events that occur once a clinically stable MS patient discontinues therapy are poorly understood in the medical community. In this study, researchers conducted a multi-site, international analysis with 181 MS patients from the ongoing, observational database MSBase Registry and assessed rates of disease relapse and disability progression in patients who had abandoned treatment. Participants were aged 40 or older, had a stable disability progression for at least 5 years with no relapses and were under disease-modifying medication for at least 3 years. Once patients discontinued medication, they were followed-up for at least three years. [adrotate group=”4″] Researchers found that after stopping medication, 24% of the patients had a clinician-reported relapse, 32% had sustained three-month disability progression and 10.6% experienced both relapses and disability progression. After a median of 22 months, 42% of the patients (77 individuals) restarted treatment, whichĀ was found to be linked to a 59% reduction in the risk of disability progression. āDespite long periods of disease stability while taking medication, we found a large minority of patients who stopped, experienced relapses or disability progression,ā concluded Dr. Kister. āWe need to identify situations when it is safe for patients with MS to stop taking these medications.ā The research team suggests that further studies should be conducted on the discontinuation of therapy in MS patients to determine when it might actually be a safe option for the patients to stop theirĀ medication. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags disability progression, medication, multiple sclerosis, relapse
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients